Active Ingredient(s): Idarucizumab
FDA Approved: * October 16, 2015
Category: Blood Clotting (Hemostasis)

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Praxbind Overview

Idarucizumab, sold under the brand name Praxbind, is a monoclonal antibody used as a reversal agent for dabigatran.[1] Idarucizumab was developed by Boehringer Ingelheim. One study sponsored by the manufacturer found that idarucizumab effectively reversed anticoagulation caused by dabigatran within minutes.[3] It was approved by the U.S. Food and Drug Administration (FDA) in October 2015.[4] Contents 1 Society and culture 1.1 Names 2 See al...

Read more Praxbind Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Praxbind Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 2.5g/50ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Praxbind: (1 result)

Sorted by National Drug Code
  • 0597-0197 Praxbind 2.5 g/ml Intravenous Injection by Boehringer Ingelheim Pharmaceuticals, Inc.

Other drugs which contain Idarucizumab or a similar ingredient: (1 result)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 18 April 2021.

We are committed to your privacy.

Copyright © 2005-2021 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA